January 15, 2020 by Stephen Ubl
Pharmaceutical Research and Manufacturers of America, Stephen Ubl
January 6, 2020, Opinion

Not so long ago, people diagnosed with hepatitis C faced a lifetime of serious complications. The virus would progress slowly, and over time, could cause extensive liver damage. But that’s not the case anymore for the vast majority of patients with the disease. Thanks to medical research and innovation over the past 25 years, patients
January 14, 2019 by Stephen Ubl
Pharmaceutical Research and Manufacturers of America, Stephen Ubl
Featured Articles, January 7, 2019, Leading Headlines, Pharmacy

Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. Pharmacists are medication experts. Every day, they get to see the remarkable difference innovative treatments can make in their customers’ lives. But like America’s biopharmaceutical companies, they also know those innovative medicines aren’t nearly as meaningful if they are too
May 9, 2018 by Chain Drug Review
Medicare Part D, Pharmaceutical Research and Manufacturers of America
Leading Headlines, Pharmacy

WASHINGTON — Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) launched the “Let’s Talk About Medicare” advertising campaign focused on solutions to improve affordability and predictability for seniors in Medicare Part D. Similar to how the “Let’s Talk About Cost” campaign opened up a conversation about costs and prescription drug coverage, this campaign builds on
February 26, 2018 by Geoff Walden and Chain Drug Review
Affordable Care Act, Avalere, CHRONIC Act, CREATES Act, Daniel Mendelson, federal budget legislation, health care spending, Independent Payment Advisory Board, Medicare Part D, Pharmaceutical Research and Manufacturers of America, Stephen Ubl
2018, Issue 02-26-2018, Issues, Leading Headlines, News, Pharmacy, Retail News

WASHINGTON — Health care spending has been beefed up in some areas and reduced in others as a result of the federal budget legislation passed by Congress earlier this month. Chronic care funding was bolstered by the two-year spending plan, which was signed into law by President Trump, while some Affordable Care Act appropriations were
January 26, 2018 by CDR Blog and Chain Drug Review
cost and coverage of prescription medications, Follow The Dollar, Holly Campbell, LetsTalkAboutCost.org, Pharmaceutical Research and Manufacturers of America, PhRMA, prescription drug costs, prescription drug pricing
CDR Blog

A new website from the Pharmaceutical Research and Manufacturers of America (PhRMA) aims to give consumers a better grasp of why prescription drugs cost so much in the United States. Launched this week, the LetsTalkAboutCost.org site takes an interactive approach by engaging visitors in a Q&A about the cost and coverage of prescription medications, with a goal
December 14, 2017 by Chain Drug Review
Addiction Policy Forum, Jessica Hulsey Nickel, opioid abuse, Pharmaceutical Research and Manufacturers of America, PhRMA, Stephen Ubl
Pharmacy, Supplier News

WASHINGTON — The Pharmaceutical Research and Manufacturers of America (PhRMA) has launched a multiyear, multimillion-dollar initiative to help tackle the opioid abuse epidemic. PhRMA said this week that the effort includes a partnership with the Addiction Policy Forum to fund state and local programs, plus support for new public policies that help families and individuals
October 16, 2017 by Chain Drug Review
Amgen, James Robinson, Joaquin Duato, Joseph Jimenez, Olivier Brandicourt, Pharmaceutical Research and Manufacturers of America, PhRMA, Robert Bradway, Stephen Ubl
Pharmacy, Supplier News

WASHINGTON — Pharmaceutical Research and Manufacturers of America (PhRMA) has named Amgen Inc. chairman and chief executive officer Robert Bradway as chairman-elect. Bradway will succeed Joaquin Duato, executive vice president and worldwide chairman of pharmaceuticals at Johnson & Johnson, as PhRMA chairman in February 2018. Previously, Bradway served as board treasurer for PhRMA. Sanofi CEO
August 17, 2017 by Stephen Ubl and Chain Drug Review
Pharmaceutical Research and Manufacturers of America, PhRMA, Stephen Ubl
Opinion

Every day at America’s community pharmacies, patients pay a bigger and bigger share of the cost for their prescription medications. But two new studies have revealed one of the puzzling reasons why — and how market-based solutions could help ease the strain on America’s patients. Like any complex U.S. industry, the biopharmaceutical sector relies on
June 9, 2017 by CDR Blog and Chain Drug Review
AAM, Alex Brill, Association for Accessible Medicines, Chip Davis, Matrix Global Advisors, new generic drugs, Pharmaceutical Research and Manufacturers of America, PhRMA, REMS, REMS and Restricted Distribution Programs, Risk Evaluation Mitigation Strategies
CDR Blog

The Association for Accessible Medicines (AAM) said a new report shows that abuse of the Food and Drug Administration’s Risk Evaluation Mitigation Strategies (REMS) safety program is hampering the market entry of new generic drugs. This week, AAM said a report by Alex Brill, CEO of economic policy consultancy Matrix Global Advisors, titled “REMS and
May 11, 2017 by Chain Drug Review
Joaquin Duato, Pharmaceutical Research and Manufacturers of America, PhRMA, PhRMA membership, Stephen Ubl
Pharmacy, Supplier News

WASHINGTON — The Pharmaceutical Research and Manufacturers of America (PhRMA) this week approved new criteria for membership. With the move, biopharmaceutical companies will have to meet new research-and-development requirements to be eligible to join the organization. PhRMA said the updated membership criteria, which go into effect immediately, came after a three-month review by its board
April 10, 2017 by Chain Drug Review
drug rebate pass-through, Pharmaceutical Research and Manufacturers of America, PhRMA, Share the Savings, Stephen Ubl
Pharmacy, Supplier News

WASHINGTON — The Pharmaceutical Research and Manufacturers of America (PhRMA) has kicked off “Share the Savings,” a new campaign to educate consumers about the lack of drug rebate pass-through for commercially insured patients with high deductibles and coinsurance. PhRMA said a collection of advertisements will be featured in print, radio, digital and social channels throughout
February 2, 2017 by Stephen Ubl and Chain Drug Review
chain drug store customers, global medicines pipeline, personalized medicines, Pharmaceutical Research and Manufacturers of America, PhRMA, Stephen Ubl
Opinion

When chain drug store customers are waiting in line at the pharmacy, odds are they have at least one thing on their mind: relief for their disease or condition. The good news is that at the start of 2017, America’s chain drug store customers will see more available treatment options than at any other time
February 1, 2017 by Chain Drug Review
Joaquin Duato, Joseph Jimenez, Pharmaceutical Research and Manufacturers of America, PhRMA, Robert Bradway, Stephen Ubl, UCB
Pharmacy, Supplier News

WASHINGTON — The Pharmaceutical Research and Manufacturers of America (PhRMA) board of directors has elected new officers and ushered in a new member company. Joaquin Duato, worldwide chairman of pharmaceuticals at Johnson & Johnson, was elected chairman. Joseph Jimenez, chief executive officer of Novartis AG, was elected chairman-elect, and Amgen chairman and CEO Robert Bradway
January 31, 2017 by Chain Drug Review
Donald Trump, pharmaceutical industry, Pharmaceutical Research and Manufacturers of America, PhRMA, Stephen Ubl, video
Videos

In a meeting with pharmaceutical industry leaders, President Donald Trump decried the high cost of drugs but said his administration would work to make it easier to get new, innovative medications to market. The Pharmaceutical Research and Manufacturers of America (PhRMA), which along with drug company executives met with Trump at the White House on